Aptose Says Tusepetinib Preclinical Data Published in AACR Journal

MT NewswiresDec 12 11:33 ET

H.C. Wainwright Maintains Aptose Biosciences(APTO.US) With Buy Rating, Maintains Target Price $2

Moomoo NewsDec 10 06:31 ET · Ratings

Aptose Presents Data At ASH 2024 Supporting Tuspetinib Triple Therapy With Venetoclax And Azacitidine In Newly Diagnosed AML, Highlighting Broad Efficacy In FLT3 Wildtype And Prior-VEN Failure Populations, Favorable Safety, And Potential To Establish...

BenzingaDec 9 12:03 ET

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

GlobeNewswireDec 9 12:00 ET

Strategic Collaboration and Promising Pipeline Drive Buy Rating for Aptose Biosciences

TipRanksDec 5 10:26 ET · Ratings

Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials

MT NewswiresDec 3 07:59 ET